SCHEMBL2995784

SCHEMBL2995784

COCC[C@H](NC(=O)c1ccc(C(=O)N2CCCC2)c(C)c1)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 2/20 0.45
ALOX12 P18054 1/20 0.45
APOBEC3A P31941 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.40
FPR1 P21462 2/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
HRH4 Q9H3N8 3/20 0.39
HRH3 Q9Y5N1 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
LMNA P02545 1/20 0.37
APLNR P35414 3/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999505 0.94 KMT2A (0.42) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL2991737 0.94 KMT2A (0.42) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL14177385 0.94 MEN1 (0.45) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL3001491 0.92 KMT2A (0.46) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL5104020 0.92 KMT2A (0.46) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL5110653 0.91 KMT2A (0.46) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL5103466 0.91 KMT2A (0.46) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL5104156 0.90 KMT2A (0.45) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL3001506 0.90 KMT2A (0.45) KMT2AALDH1A1MEN1ALOX12APOBEC3A
SCHEMBL5100759 0.90 MEN1 (0.45) KMT2AALDH1A1MEN1ALOX12APOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases EISERT WOLFGANG 2009-03-19 US claimed
US-7326791-B2 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-02-05 US claimed
US-20040220169-A1 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-11-04 US claimed
US-20100184729-A1 New Pharmaceutical Compositions for Treatment of Thrombosis BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-22 US disclosed
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases EISERT WOLFGANG 2009-03-19 US disclosed
US-20090048173-A1 Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors EISERT WOLFGANG 2009-02-19 US disclosed
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-06-05 US disclosed
US-7326791-B2 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-02-05 US disclosed
US-20060222640-A1 NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 KMT2A 3087/4885ALDH1A1 328/4885MEN1 1667/4885
US-20090048173-A1 Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors ANXA5, F5, ANXA3 KMT2A 3608/4885ALDH1A1 3876/4885MEN1 2079/4885
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases PEPD, PLAT, TFPI KMT2A 3592/4885ALDH1A1 1111/4885MEN1 1649/4885
US-20100184729-A1 New Pharmaceutical Compositions for Treatment of Thrombosis PROC, F12, SERPINC1 KMT2A 4723/4885ALDH1A1 4552/4885MEN1 4422/4885
US-20060222640-A1 NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS PROC, F12, SERPINC1 KMT2A 4723/4885ALDH1A1 4552/4885MEN1 4422/4885
US-20040220169-A1 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions F12, F11, F2 KMT2A 3716/4885ALDH1A1 143/4885MEN1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.